Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VKTX
CUSIPN/A
Phone858-704-4660
Debt
Debt-to-Equity RatioN/A
Current Ratio35.18
Quick Ratio35.18
Price-To-Earnings
Trailing P/E Ratio-17.97
Forward P/E Ratio-32.27
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.38 per share
Price / Book37.37
Profitability
EPS (Most Recent Fiscal Year)($0.79)
Net Income$-20,570,000.00
Net MarginsN/A
Return on Equity-35.70%
Return on Assets-31.72%
Miscellaneous
Employees12
Outstanding Shares60,660,000
Market Cap$1.06 billion
Viking Therapeutics (NASDAQ:VKTX) Frequently Asked Questions
What is Viking Therapeutics' stock symbol?
Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."
How were Viking Therapeutics' earnings last quarter?
Viking Therapeutics Inc (NASDAQ:VKTX) posted its earnings results on Thursday, August, 9th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by $0.02. View Viking Therapeutics' Earnings History.
When is Viking Therapeutics' next earnings date?
What price target have analysts set for VKTX?
7 analysts have issued 1 year price targets for Viking Therapeutics' stock. Their predictions range from $15.00 to $43.00. On average, they expect Viking Therapeutics' share price to reach $28.1667 in the next year. This suggests a possible upside of 98.4% from the stock's current price. View Analyst Price Targets for Viking Therapeutics.
What is the consensus analysts' recommendation for Viking Therapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Viking Therapeutics.
What are Wall Street analysts saying about Viking Therapeutics stock?
Here are some recent quotes from research analysts about Viking Therapeutics stock:
- 1. Maxim Group analysts commented, "VKTX shares are up sharply (~+80%) after announcing positive top-line 12- week P2 data for VK2809, an oral thyroid beta receptor agonist (TRβ), in Non- Alcoholic Fatty Liver Disease (NAFLD) and elevated LDL-C. We have reduced the risk in our model to 30%, from 50% and are increasing our price target to $28, from $14." (9/18/2018)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $15 price target. Our price target is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway. Viking Therapeutics, Inc." (8/10/2018)
Are investors shorting Viking Therapeutics?
Viking Therapeutics saw a increase in short interest during the month of September. As of September 28th, there was short interest totalling 15,356,397 shares, an increase of 46.9% from the September 14th total of 10,452,068 shares. Based on an average daily trading volume, of 12,098,882 shares, the days-to-cover ratio is presently 1.3 days. Approximately 24.7% of the shares of the company are sold short. View Viking Therapeutics' Current Options Chain.
Who are some of Viking Therapeutics' key competitors?
Some companies that are related to Viking Therapeutics include Taro Pharmaceutical Industries (TARO), Ultragenyx Pharmaceutical (RARE), Endo International (ENDP), Intercept Pharmaceuticals (ICPT), Blueprint Medicines (BPMC), Emergent Biosolutions (EBS), Madrigal Pharmaceuticals (MDGL), Horizon Pharma (HZNP), Array Biopharma (ARRY), Evotec (EVTCY), Akcea Therapeutics (AKCA), Ascendis Pharma A/S (ASND), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN) and Myokardia (MYOK).
Who are Viking Therapeutics' key executives?
Viking Therapeutics' management team includes the folowing people:
- Dr. Brian Lian, Pres, CEO & Director (Age 52)
- Mr. Michael Morneau, VP of Fin. & Admin. (Age 53)
- Ms. Amy Broidrick, Sr. VP of Corp. Devel.
- Dr. Hiroko Masamune, Chief Devel. Officer (Age 61)
- Ms. Marianne Mancini, Sr. VP of Clinical Operations
When did Viking Therapeutics IPO?
(VKTX) raised $20 million in an initial public offering (IPO) on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO and Feltl and Company was co-manager.
Who are Viking Therapeutics' major shareholders?
Viking Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include First Manhattan Co. (0.33%) and Bank of Montreal Can (0.07%). Company insiders that own Viking Therapeutics stock include J Matthew Singleton, Lawson Macartney, Ligand Pharmaceuticals Inc, Matthew W Foehr and Michael Morneau. View Institutional Ownership Trends for Viking Therapeutics.
Which major investors are selling Viking Therapeutics stock?
VKTX stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co. and Bank of Montreal Can. Company insiders that have sold Viking Therapeutics company stock in the last year include Ligand Pharmaceuticals Inc and Michael Morneau. View Insider Buying and Selling for Viking Therapeutics.
How do I buy shares of Viking Therapeutics?
Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Viking Therapeutics' stock price today?
One share of VKTX stock can currently be purchased for approximately $14.20.
How big of a company is Viking Therapeutics?
Viking Therapeutics has a market capitalization of $1.06 billion. The biotechnology company earns $-20,570,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Viking Therapeutics employs 12 workers across the globe.
What is Viking Therapeutics' official website?
How can I contact Viking Therapeutics?
Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-704-4660 or via email at [email protected]
MarketBeat Community Rating for Viking Therapeutics (NASDAQ VKTX)
MarketBeat's community ratings are surveys of what our community members think about Viking Therapeutics and other stocks. Vote "Outperform" if you believe VKTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VKTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
